PONIARD PHARMACEUTICALS REPORTS 2ND QTR NET LOSS OF $8.5
MIL.(Financial report)
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical
company focused on oncology, has reported on its corporate progress and
financial results for the quarter ended June 30, 2007.
. . .
TARGACEPT REPORTS 2ND QTR 2007 NET LOSS OF $8.3
MILLION.(Financial report)
Targacept, Inc. (NASDAQ: TRGT), Winston-Salem, N.C., a
clinical-stage biopharmaceutical company developing a new class of drugs
known as NNR Therapeutics(TM), has reported its financial results . . .
ALEXION INCURS A 2ND QTR 2007 NET LOSS OF $27.2
MILLION.(Financial report)
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Cheshire, Conn., has
announced financial results for the quarter ended June 30, 2007.
Second Quarter Highlights:
* During April 2007, Alexion . . .
BIOMET REPORTS 4TH QTR NET SALES INCREASED 2%.(Financial
report)
During the fourth quarter of fiscal year 2007, net sales increased
2% to $549,407,000. Excluding the impact of foreign currency, which
increased fourth quarter revenues by approximately $15.8 . . .
IVIVI TECHNOLOGIES REPORTS FISCAL 07 50% INCREASE IN
REVENUE.(Financial report)
Ivivi Technologies, Inc. (AMEX:II), Northvale, N.J., a leader in
non-invasive, electrotherapeutic technologies, has announced financial
results for fiscal year ended March 31, 2007.
For the . . .
CLEARANT REPORTS RECORD FIRST QTR 2007 RESULTS.
Clearant, Inc. (OTCBB:CLRI), Los Angeles, has announced record
total revenue for the first quarter 2007. This is the third consecutive
quarter over quarter revenue growth and direct distribution . . .
POSSIS MEDICAL REPORTS 3RD QTR NET SALES UP 7%.(Financial
report)(Clinical report)
Possis Medical, Inc. (NASDAQ:POSS), Minneapolis a, developer,
manufacturer and marketer of pioneering medical devices used in
endovascular procedures, has reported results for its fiscal 2007 . . .
TEMPO PHARMACEUTICALS CLOSES $12.1 MIL IN SERIES A
FUNDING.
Tempo Pharmaceuticals, Cambridge, Mass., a biopharmaceutical
company focused on novel, intelligently designed nanoparticle-based
drugs, has closed a $12.1 million Series A financing. Proceeds from . . .
AMGEN'S FIRST QTR 2007 REVENUE INCREASED 15% TO $3.7
BIL.(Financial report)
Amgen (NASDAQ:AMGN), Thousand Oaks, Calif., reported adjusted
earnings per share (EPS), excluding stock option expense and certain
other expenses, of $1.08 for the first quarter of 2007, an . . .
ARRAY BIOPHARMA REPORTS 3RD QTR NET LOSS OF 14 MILLION.(Financial
report)
Array BioPharma Inc.,(NASDAQ: ARRY), Boulder, Colo., has reported
financial results for the third quarter of fiscal 2007. Array reported
revenue of $10.4 million for the third quarter of fiscal . . .
AVIGEN REPORTS FIRST QTR 2007 NET LOSS OF $5.8 MILLION.(Financial
report)
Avigen, Inc. (Nasdaq:AVGN), Alameda, Calif., a biopharmaceutical
company developing innovative therapies for the treatment of chronic
neurological conditions, today reported financial results for . . .
INTERMUNE UPDATES EXPENSE FORECASTS/DEVELOPMENT PLANS.
InterMune, Inc. (NASDAQ:ITMN), Brisbane, Calif. has completed a
review of its research and development programs and infrastructure
requirements. InterMune will implement a number of operational . . .
OSCIENT EXPECTS TOTAL REVENUES OF $23 MILLION FOR Q1
2007.(Oscient Pharmaceuticals Corporation)
Oscient Pharmaceuticals Corporation (Nasdaq: OSCI), Waltham, Mass.,
has announced preliminary revenue for the first quarter of 2007. The
company expects to record total revenues of approximately . . .
AURIGA LABS REPORTS RECORD 2007 FIRST QTR RESULTS.(Financial
report)
Auriga Laboratories, Inc., (OTCBB:ARGA), Los Angeles, a specialty
pharmaceutical company with products for the treatment of Xerostomia,
dermatological conditions, and acute respiratory diseases, . . .
IKARIA\INVESTOR GROUP TO AQCUIRE INO THERAPEUTICS.
Ikaria Holdings, a newly formed investment company, has announced
the signing of a definitive agreement to combine Ikaria Inc., a
biotechnology company, and INO Therapeutics, the world leader in . . .
HELIX BIOPHARM HAS 2ND QTR FISCAL 2007 $1,900,000 LOSS.(Financial
report)
Helix BioPharma Corp. (TSX: HBP/Frankfurt: WKN 918864), Aurora,
Ont., has announced financial results for the second quarter of fiscal
2007, ended January 31, 2007.
RESULTS FROM OPERATIONS
. . .
NORTH AMERICAN SCIENTIFIC HAS FIRST QTR FISCAL 2007 NET
LOSS.(Financial report)
North American Scientific, Inc. (Nasdaq: NASI), Chatsworth, Calif.
has announced financial results for its fiscal first quarter ended
January 31, 2007. For the first quarter of fiscal 2007, the . . .
BAXTER'S ACHIEVED RECORD SALES/EARNINGS IN 2006.(Financial
report)
Baxter International Inc. (NYSE:BAX), Deerfield, Ill., has reported
financial results for the fourth quarter 2006 and provided its financial
outlook for the first quarter and full- year 2007.
. . .
PAREXEL REPORTS 2ND QTR FISCAL 2007 NET INCOME OF $9.1
MIL.(Company overview)(Financial report)
PAREXEL International Corporation (NASDAQ:PRXL), Boston, Mass. has
announced its financial results for the second quarter ended December
31, 2006.
For the three months ended December 31, 2006, . . .
SURMODICS REPORTS 23% GROWTH IN NON-CYPHER REVENUE.(Financial
report)
SurModics, Inc. (Nasdaq: SRDX), Eden Prairie, Minn., a leading
provider of surface modification and drug delivery technologies to the
healthcare industry, has reported financial results for the . . .
|
|